Demographic and Clinical Characteristics of COVID-19 Patients with Mucormycosis

Moshki, Ali; Mohammadi, Soha; Salehi, Tayebe; Divsalar, Farshad; Abbasi, Mohammad Amin

doi:10.61186/rabms.10.3.233

Volume 10, Issue 3 (7-2024) Journal of Research in Applied and Basic Medical Sciences 2024, 10(3): 233-239 | Back to browse issues page

‎ 10.61186/rabms.10.3.233

Ethics code: IR.IUMS.FMD.REC.1401.066

Mendeley

Zotero

RefWorks

Moshki A, Mohammadi S, Salehi T, Divsalar F, Abbasi M A. Demographic and Clinical Characteristics of COVID-19 Patients with Mucormycosis. Journal of Research in Applied and Basic Medical Sciences 2024; 10 (3) :233-239
URL: http://ijrabms.umsu.ac.ir/article-1-277-en.html

Demographic and Clinical Characteristics of COVID-19 Patients with Mucormycosis

Ali Moshki ^*

, Soha Mohammadi

, Tayebe Salehi

, Farshad Divsalar

, Mohammad Amin Abbasi

Department of Anesthesiology and Pain Medicine, Hasheminejad Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran , a.moshki@gmail.com

Abstract: (519 Views)

Background & Aims: Mucormycosis, commonly known as "Black Fungus," is an angio-invasive fungus and has become a significant concern during the Coronavirus disease 2019 (COVID-19) pandemic. This study aimed to determine the prevalence rate of mucormycosis and related risk factors among COVID-19 patients, making an essential contribution to further understanding this opportunistic disease.
Methods & Materials: This descriptive-analytical cross-sectional study was carried out among 276 patients. Patients were divided into two groups according to the presence of mucormycosis. The diagnosis of mucormycosis was established through a combination of clinical symptoms, imaging findings, and microbiological confirmation. The study examined demographic and clinical characteristics of the patients, including age, gender, duration of hospitalization, and laboratory results, such as C-reactive protein (CRP) and blood sugar levels. The statistical analysis was performed using the SPSS Statistics software package (version 26). Statistical significance was set at a P-value of 0.05.
Results: The mean age of patients participating in the study was 59±16 years. Among them, 158 patients (57.2%) were male, and 20 (7.2%) were diagnosed with mucormycosis. The analysis revealed a significant association between mucormycosis presence and various demographic and clinical variables, notably impacting hospitalization duration, blood sugar level, and serum CRP level.
Conclusion: Findings from our study indicate that elevated CRP and blood sugar levels, as well as prolonged hospitalization, are significant risk factors for mucormycosis in the patients.

Keywords: Blood Sugar, C-Reactive Protein, Coronavirus Infection, Corticosteroids, Mucormycosis, Opportunistic Infection

Full-Text [PDF 239 kb] (147 Downloads)

Type of Study: orginal article | Subject: Virology

References

1. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999;159(12):1301-9. [DOI:10.1001/archinte.159.12.1301] [PMID]

2. Yamin HS, Alastal AY, Bakri I. Pulmonary mucormycosis over 130 years: a case report and literature review. Turk Thorac J 2017;18(1):1. [DOI:10.5152/TurkThoracJ.2017.16033] [PMID] []

3. Cummings CW. Otolaryngology Head & Neck Surgery, Vol-5. [URL]

4. Mohamadi GR, Kavosi A, Raziani Y, Parvinian AMN. Rhinocerebral mucormycosis and treatment: Report of two cases. J Neyshabur Univ Med Sci 2014;2(2):10-13. [URL]

5. Dogra S, Arora A, Aggarwal A, Passi G, Sharma A, Singh G, Barnwal RP. Mucormycosis amid COVID-19 crisis: pathogenesis, diagnosis, and novel treatment strategies to combat the spread. Front. Microbiol 2022;12:4005. [DOI:10.3389/fmicb.2021.794176] [PMID] []

6. Galetta SL, Wulc AE, Goldberg HI, Nichols CW, Glaser JS. Rhinocerebral mucormycosis: management and survival after carotid occlusion. Ann Neurol 1990;28(1):103-7. [DOI:10.1002/ana.410280121] [PMID]

7. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18(3):556-69. [DOI:10.1128/CMR.18.3.556-569.2005] [PMID] []

8. Stratton CW, O'Hare M. Topics in clinical microbiology histopathologic diagnosis of fungal diseases. Infect Control 1986;7(2):78-84 [DOI:10.1017/S0195941700063943]

9. Mohammadi SH, Daneshi A, Javadi M. Orbitorhinocereberal mucormycosis: report of 9 cases. Razi J Med Sci 2002;8(26):397-407. [PMCID]

10. Rajic J, Gmizic I, Gunjak T, Milosevic V, Pantic N, Sabljic N, Mitrovic M, Djuric Stefanovic A, Lazic L, Jovanovic S, Milošević I. Covid-19-associated pulmonary aspergillosis in patients with acute leukemia: a single-center study. J Fungi 2021;7(11):890. [DOI:10.3390/jof7110890] [PMID] []

11. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727-33. [DOI:10.1056/NEJMoa2001017] [PMID] []

12. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009;15(9):1395. [DOI:10.3201/eid1509.090334] [PMID] []

13. Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D, Chouhan R, Bhat R, Mathew R, Majeed JA, Aggarwal P. COVID-19-associated mucormycosis presenting to the Emergency Department-an observational study of 70 patients. Int J Med 2021;114(7):464-70. [DOI:10.1093/qjmed/hcab190] [PMID] []

14. Gupta R, Kesavadev J, Krishnan G, Agarwal S, Saboo B, Shah M, Mittal A, Durani S, Luthra A, Singhal A, Rasheed M. COVID-19 associated mucormycosis: a descriptive multisite study from India. Diabetes Metab. Syndr. Clin Res Rev 2021;15(6):102322. [DOI:10.1016/j.dsx.2021.102322] [PMID] []

15. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, Savio J, Sethuraman N, Madan S, Shastri P, Thangaraju D, Marak R, Tadepalli K, Savaj P, Sunavala A, Gupta N, Singhal T, Muthu V, Chakrabarti A; MucoCovi Network3. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. Emerg Infect Dis 2021;27(9):2349-59. [DOI:10.3201/eid2709.210934] [PMID] []

16. Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 2022;3(7):e543-e52. [DOI:10.1016/S2666-5247(21)00237-8] [PMID]

17. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol 2021;69(2):244-52. [DOI:10.4103/ijo.IJO_3774_20] [PMID] []

18. Chander J, Kaur M, Singla N, Punia RP, Singhal SK, Attri AK, Alastruey-Izquierdo A, Stchigel AM, Cano-Lira JF, Guarro J. Mucormycosis: battle with the deadly enemy over a five-year period in India. J Fungi 2018;4(2):46. [DOI:10.3390/jof4020046] [PMID] []

19. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DC, Chen SA. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019;25(1):26-34. [DOI:10.1016/j.cmi.2018.07.011] [PMID]